The Past, Present, and Future of Treatment Intensification for Metastatic Hormone-Sensitive Prostate Cancer.
作者信息
McManus Hannah D, Armstrong Andrew J
机构信息
Department of Medicine, Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC.
出版信息
J Clin Oncol. 2023 Jul 10;41(20):3576-3579. doi: 10.1200/JCO.23.00323. Epub 2023 Mar 22.
Abstract
摘要
相似文献
1
The Past, Present, and Future of Treatment Intensification for Metastatic Hormone-Sensitive Prostate Cancer.转移性激素敏感性前列腺癌强化治疗的过去、现在与未来
J Clin Oncol. 2023 Jul 10;41(20):3576-3579. doi: 10.1200/JCO.23.00323. Epub 2023 Mar 22.
2
Future directions in systemic treatment of metastatic hormone-sensitive prostate cancer.转移性激素敏感前列腺癌系统治疗的未来方向。
World J Urol. 2023 Aug;41(8):2021-2031. doi: 10.1007/s00345-022-04135-8. Epub 2022 Aug 27.
3
Management of Metastatic Hormone-Sensitive Prostate Cancer: Is Docetaxel Needed?转移性激素敏感性前列腺癌的管理：是否需要多西他赛？
J Clin Oncol. 2022 Nov 1;40(31):3573-3575. doi: 10.1200/JCO.22.00705. Epub 2022 Jun 20.
4
SYSTEMIC TRIPLE THERAPY IN METASTATIC HORMONE SENSITIVE PROSTATE CANCER (MHSPC).转移性激素敏感型前列腺癌的系统性三联疗法。
Acta Clin Croat. 2022 Oct;61(Suppl 3):81-85. doi: 10.20471/acc.2022.61.s3.12.
5
Metastatic Hormone-Sensitive Prostate Cancer and Combination Treatment Outcomes: A Review.转移性激素敏感型前列腺癌与联合治疗结局：综述。
JAMA Oncol. 2024 Jun 1;10(6):807-820. doi: 10.1001/jamaoncol.2024.0591.
6
The Role of Physician Specialty in the Underutilization of Standard-of-Care Treatment Intensification in Patients With Metastatic Castration-sensitive Prostate Cancer.医生专业在转移性去势敏感性前列腺癌患者标准治疗强化利用不足中的作用
J Urol. 2023 Jun;209(6):1120-1131. doi: 10.1097/JU.0000000000003370. Epub 2023 Feb 15.
7
Does Research from Clinical Trials in Metastatic Hormone-sensitive Prostate Cancer Treatment Translate into Access to Treatments for Patients in the "Real World"? A Systematic Review.转移性激素敏感型前列腺癌治疗的临床试验研究能否转化为患者在“真实世界”中获得治疗的机会？一项系统评价。
Eur Urol Oncol. 2024 Feb;7(1):14-24. doi: 10.1016/j.euo.2023.05.002. Epub 2023 Jun 27.
8
Abiraterone or Docetaxel for Castration-sensitive Metastatic Prostate Cancer? That Is the Question!阿比特龙还是多西他赛用于去势敏感性转移性前列腺癌？这是个问题！
Eur Urol. 2018 Jan;73(1):147-148. doi: 10.1016/j.eururo.2017.07.030. Epub 2017 Aug 8.
9
Qualitative and Quantitative Assessment of Patient and Carer Experience of Chemotherapy (Docetaxel) in Combination with Androgen Deprivation Therapy (ADT) for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC).转移性激素敏感型前列腺癌（mHSPC）患者接受多西他赛化疗（Docetaxel）联合雄激素剥夺治疗（ADT）的患者和照护者体验的定性和定量评估。
Adv Ther. 2018 Dec;35(12):2186-2200. doi: 10.1007/s12325-018-0825-7. Epub 2018 Nov 10.
10
Re: Darolutamide plus Androgen-deprivation Therapy and Docetaxel in Metastatic Hormone-sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial.关于：III期ARASENS试验中根据疾病体积和风险亚组分析达洛鲁胺联合雄激素剥夺疗法及多西他赛治疗转移性激素敏感性前列腺癌的研究
Eur Urol. 2023 Sep;84(3):350-351. doi: 10.1016/j.eururo.2023.04.031. Epub 2023 May 12.
引用本文的文献
1
Evolving Treatment Paradigms in Metastatic Hormone-Sensitive Prostate Cancer: Expert Narrative Review.转移性激素敏感性前列腺癌不断演变的治疗模式：专家叙述性综述
Curr Oncol. 2025 Aug 5;32(8):437. doi: 10.3390/curroncol32080437.
2
Outcomes of First Subsequent Taxane Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer Who Previously Received Docetaxel Intensification for Metastatic Castration-Sensitive Prostate Cancer.先前接受多西他赛强化治疗转移性去势敏感性前列腺癌的转移性去势抵抗性前列腺癌患者接受首次后续紫杉烷治疗的结果。
Curr Oncol. 2024 Aug 29;31(9):5080-5087. doi: 10.3390/curroncol31090375.
3
Metastatic Hormone-Sensitive Prostate Cancer in the Era of Doublet and Triplet Therapy.转移性激素敏感型前列腺癌在双药和三药治疗时代。
Curr Treat Options Oncol. 2024 Mar;25(3):293-312. doi: 10.1007/s11864-023-01173-1. Epub 2024 Jan 4.
本文引用的文献
1
Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial.在 III 期 ARASENS 试验中，根据疾病体积和风险亚组，达罗他胺联合雄激素剥夺治疗和多西他赛治疗转移性激素敏感性前列腺癌。
J Clin Oncol. 2023 Jul 10;41(20):3595-3607. doi: 10.1200/JCO.23.00041. Epub 2023 Feb 16.
2
Treatment Intensification Patterns and Utilization in Patients with Metastatic Castration-Sensitive Prostate Cancer.转移性去势敏感型前列腺癌患者的强化治疗模式和利用情况。
Clin Genitourin Cancer. 2022 Dec;20(6):524-532. doi: 10.1016/j.clgc.2022.06.017. Epub 2022 Jun 28.
3
Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer.恩杂鲁胺可改善转移性去势敏感性前列腺癌患者的生存。
J Clin Oncol. 2022 May 20;40(15):1616-1622. doi: 10.1200/JCO.22.00193. Epub 2022 Apr 14.
4
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.阿比特龙联合泼尼松加至去势治疗和多西他赛用于初治转移性去势敏感性前列腺癌（PEACE-1）：一项采用2×2析因设计的多中心、开放标签、随机3期研究。
Lancet. 2022 Apr 30;399(10336):1695-1707. doi: 10.1016/S0140-6736(22)00367-1. Epub 2022 Apr 8.
5
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.达罗他胺与转移性去势敏感性前列腺癌的生存
**注**：这是基于你提供的文本进行的翻译，实际翻译可能会因上下文和语言习惯而有所不同。
N Engl J Med. 2022 Mar 24;386(12):1132-1142. doi: 10.1056/NEJMoa2119115. Epub 2022 Feb 17.
6
Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy.转移性去势敏感性前列腺癌患者接受恩杂鲁胺和雄激素剥夺治疗的总生存情况。
Eur Urol. 2021 Sep;80(3):275-279. doi: 10.1016/j.eururo.2021.05.016. Epub 2021 May 22.
7
Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study.阿帕鲁胺治疗转移性去势敏感性前列腺癌患者的生存分析：随机、双盲、III 期 TITAN 研究的最终生存分析。
J Clin Oncol. 2021 Jul 10;39(20):2294-2303. doi: 10.1200/JCO.20.03488. Epub 2021 Apr 29.
8
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.恩扎卢胺联合标准一线治疗转移性前列腺癌。
N Engl J Med. 2019 Jul 11;381(2):121-131. doi: 10.1056/NEJMoa1903835. Epub 2019 Jun 2.
9
Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial.醋酸阿比特龙联合泼尼松治疗新诊断的高危转移性去势敏感性前列腺癌（LATITUDE）：一项随机、双盲、III 期临床试验的最终总生存分析。
Lancet Oncol. 2019 May;20(5):686-700. doi: 10.1016/S1470-2045(19)30082-8. Epub 2019 Apr 12.
10
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.新诊断转移性前列腺癌原发肿瘤放疗（STAMPEDE）：一项随机对照 3 期试验。
Lancet. 2018 Dec 1;392(10162):2353-2366. doi: 10.1016/S0140-6736(18)32486-3. Epub 2018 Oct 21.
Zotero 插件